Yang, M., Huang, C., Chang, D., Hu, F., Huang, S., Huang, P., . . . Lu, Y. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis. Wiley.
Chicago Style (17th ed.) CitationYang, Ming‐Han, et al. Concurrent Epirubicin and Trastuzumab Use Increases Complete Pathological Response Rate Without Additional Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2‐positive Early Breast Cancer: A Meta‐regression Analysis. Wiley.
MLA (9th ed.) CitationYang, Ming‐Han, et al. Concurrent Epirubicin and Trastuzumab Use Increases Complete Pathological Response Rate Without Additional Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2‐positive Early Breast Cancer: A Meta‐regression Analysis. Wiley.